Stock Watch: Pandemic Lessons For Smaller Commercial Biotechs
Neurocrine And Clovis Are Still Deep In Pandemic Pressures
Recently launched branded drugs prescribed by specialist physicians and marketed by smaller commercial-stage biotech companies remain in the eye of the pandemic storm.
You may also be interested in...
An early high for Pfizer with its strong first-quarter results was followed by patent waiver worries. At the other end of the spectrum, Esperion reminded us of the challenges in making a commercial success as a small biopharma firm in the pandemic.
Biogen’s recent contentious approval put the cat amongst the pigeons in the debate on surrogate markers as a basis for accelerated approval. The history of such approvals goes back to the last century.
Factors in addition to the rejuvenation of pharmaceutical revenues and biotechnology product failures are likely to pull in opposite directions at the sector’s recovery from the pandemic.